Clinical-Trial Delays and Declining Sales Due to COVID-19
First written in FY2021. 2 of 6 entries say "Restated". Latest entry: FY2023.
The whole theme swung hardest in 2022: 4 of 20 companies on the "Worse" side.
6 other companies' latest entry also says "Mitigated".
- FY2023MitigatedAnnual report
「During the fiscal year, the economy, which had stagnated because of the spread of COVID-19, showed signs of recovery, and sales of antibody reagents returned to pre-pandemic levels.」
Sales of antibody reagents, which had declined amid the spread of COVID-19, returned to pre-pandemic levels. - FY2022MitigatedAnnual report
「The impact of COVID-19 during the fiscal year was limited, and sales of both antibody research support services and antibody reagents began to recover.」
Although the effects of the infection remained, its impact during the fiscal year was limited, and sales of antibody research support services and reagents began to recover. - FY2022-Q3WorsenedAnnual report
「The global economy during the cumulative third quarter was still affected by COVID-19. Vaccination rates and the pace of the gradual recovery in economic activity varied, while highly transmissible variant strains caused infections to spread again in countries worldwide.」
While the impact of COVID-19 continued, renewed outbreaks caused by highly transmissible variant strains were reported in countries worldwide, indicating that the situation had progressed from concerns about renewed spread in the previous quarter to actual renewed spread. - FY2022-Q2RestatedAnnual report
「The global economy during the cumulative second quarter was still affected by COVID-19. Vaccination rates varied by country, and the pace of the gradual recovery in economic activity also varied. There were also concerns about a renewed spread of infections caused by variant strains.」
The impact of COVID-19 on the economy and business, as well as concerns about a renewed spread caused by variant strains, continued to be reported. - FY2022-Q1RestatedAnnual report
「We continued to be affected by COVID-19. Although vaccination was progressing, there were also concerns about a renewed spread of infections caused by variant strains.」
Reaffirming that the impact of COVID-19 continued and that there were concerns about a renewed spread of infections caused by variant strains. - FY2021First statedAnnual report
「COVID-19 affected our pharmaceutical development activities, including by causing clinical trials to be suspended. The Phase I trial in healthy subjects for pipeline product PPMX-T003 also ended approximately 4 months behind schedule. Sales of antibody reagents to researchers worldwide also declined, as research activities at universities and other research institutions around the world were disrupted.」
The suspension and approximately 4-month delay in clinical trials, as well as the decline in antibody reagent sales caused by stagnating research activities, actually occurred.